Investors aiming for above-average returns often turn to the practice of stock picking. Skillful choices in individual stocks can be a catalyst for substantial wealth growth.
As of close of business last night, LENZ Therapeutics Inc’s stock clocked out at $38.63, up 1.13% from its previous closing price of $38.2. In other words, the price has increased by $1.13 from its previous closing price. On the day, 0.2 million shares were traded. LENZ stock price reached its highest trading level at $38.87 during the session, while it also had its lowest trading level at $37.835.
Ratios:
To gain a deeper understanding of LENZ’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 20.54 and its Current Ratio is at 20.54. In the meantime, Its Debt-to-Equity ratio is 0.01 whereas as Long-Term Debt/Eq ratio is at 0.00.
On March 18, 2025, TD Cowen started tracking the stock assigning a Buy rating and target price of $60.
On September 27, 2024, Raymond James started tracking the stock assigning a Outperform rating and target price of $37.Raymond James initiated its Outperform rating on September 27, 2024, with a $37 target price.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Aug 25 ’25 when Versant Venture Capital VI, L. sold 52,419 shares for $39.54 per share. The transaction valued at 2,072,738 led to the insider holds 1,321,640 shares of the business.
Versant Venture Capital VI, L. sold 47,443 shares of LENZ for $1,850,891 on Aug 26 ’25. The 10% Owner now owns 1,274,197 shares after completing the transaction at $39.01 per share. On Aug 22 ’25, another insider, Versant Venture Capital VI, L., who serves as the 10% Owner of the company, sold 26,161 shares for $40.15 each. As a result, the insider received 1,050,392 and left with 1,374,059 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, LENZ now has a Market Capitalization of 1101808768 and an Enterprise Value of 893340544. For the stock, the TTM Price-to-Sale (P/S) ratio is 220.36 while its Price-to-Book (P/B) ratio in mrq is 5.34. Its current Enterprise Value per Revenue stands at 178.668 whereas that against EBITDA is -14.439.
Stock Price History:
The Beta on a monthly basis for LENZ is 0.55, which has changed by 0.7002641 over the last 52 weeks, in comparison to a change of 0.16844666 over the same period for the S&P500. Over the past 52 weeks, LENZ has reached a high of $41.70, while it has fallen to a 52-week low of $16.53. The 50-Day Moving Average of the stock is 13.95%, while the 200-Day Moving Average is calculated to be 32.59%.
Shares Statistics:
It appears that LENZ traded 459.99K shares on average per day over the past three months and 517990 shares per day over the past ten days. A total of 28.50M shares are outstanding, with a floating share count of 24.04M. Insiders hold about 16.37% of the company’s shares, while institutions hold 92.20% stake in the company. Shares short for LENZ as of 1755216000 were 4818822 with a Short Ratio of 10.48, compared to 1752537600 on 3847661. Therefore, it implies a Short% of Shares Outstanding of 4818822 and a Short% of Float of 31.290000000000003.
Earnings Estimates
The market rating for LENZ Therapeutics Inc (LENZ) is a result of the insights provided by 5.0 analysts actively involved in the assessment.The consensus estimate for the next quarter is -$0.77, with high estimates of -$0.63 and low estimates of -$0.87.
Analysts are recommending an EPS of between -$2.19 and -$2.75 for the fiscal current year, implying an average EPS of -$2.56. EPS for the following year is -$2.5, with 6.0 analysts recommending between -$1.75 and -$3.65.
Revenue Estimates
Based on 8 analysts’ estimates, the company’s revenue will be $49.74M in the next fiscal year. The high estimate is $60.28M and the low estimate is $41.17M.
